Raju Prasad

PTC Therapeutics, Inc. (NASDAQ: PTCT) traded sigificantly higher Monday after having published a positive update from its risdiplam trial in type 1 SMA babies. The Rating William Blair analyst Raju Prasad accordingly upgraded PTC to Outperform. The Thesis Risdiplam’s efficacy data compares...

Shares of bluebird bio Inc (NASDAQ: BLUE) gained more than 200 percent in value last year and investors can expect 2018 to be another "blue-ribbon year" for the stock, according to William Blair. The Analyst Willaim Blair's Raju Prasad initiated coverage of bluebird bio's...

Global Blood Therapeutics Inc (NASDAQ: GBT), a clinical-stage biopharmaceutical company that develops therapeutics to treat blood-based disorders, received a breakthrough therapy designation in early January that has at least one analyst optimistic as to what will come next. The Analyst William...